Dr. Zakharia on phase 2 study of durvalumab and RT in urothelial cancer

At the time of data cutoff, 71% of patients achieved a complete response following treatment.

In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.

At the end of the induction phase, 86% of patients had achieved a complete response.

“It's not a replacement for clinical judgment, obviously. But at the end of the day, the idea is that it shows you what your next steps are based on what the American Urological Association and [Society of Urologic Oncology] guidelines are for non-muscle invasive bladder cancer,” Chad R. Ritch, MD, MBA, FACS.

The observational LOBSTER study has already enrolled 303 patients and collected 479 samples.

Anti-tumor activity was observed across all patients with FGFR3-altered metastatic urothelial carcinoma who were treated at the dose levels of 90 mg and higher.